You are here

Share:

Search Technologies

Showing 1-20 of 32 results found

Methods of Producing Thymic Emigrants from Induced Pluripotent Stem Cells

Pluripotent stem cells are a promising source of T cells for a variety of clinical applications. However, current in vitro methods of T cell differentiation result in the generation of cells with aberrant phenotypes. Researchers at the National Cancer Institute (NCI) have now developed methodology for generating induced pluripotent stem cell thymic emigrants (iTE). Antigen-specific CD8αβ+ iTEs exhibited functional properties in vitro that were almost indistinguishable from natural naïve CD8αβ+ T cells, including vigorous expansion and robust anti-tumor activity. iTEs recapitulated many of the transcriptional programs of naïve T cells in vivo and revealed a striking capacity for engraftment, memory formation, and efficient tumor destruction. The NCI seeks licensing and/or co-development research collaborations for this invention.

Peptide Hydrogels for Rate-Controlled Delivery of Therapeutics

Scientists at the National Cancer Institute (NCI) have developed a novel delivery platform in which the scaffold of an anionic hydrogel (AcVES3) can be attenuated to deliver therapeutic small molecules, peptides, proteins, nanoparticles, or whole cells. The NCI seeks collaborators and licensees for the development of this technology in various clinical and laboratory applications.

Design and Biological Activity of Novel Stealth Polymeric Lipid Nanoparticles for Enhanced Delivery of Hydrophobic Photodynamic Therapy Drugs

Scientists at the National Cancer Institute (NCI) developed a novel stealth lipid-based nanoparticle formulation comprising phospholipid, DC8,9PC and a polyethylene glycol-ated (PEGylated) lipid – such as DSPE-PEG2000 – that efficiently package a high amounts of hydrophobic photodynamic drug (PDT) – such as HPPH – in stable vesicles. This HPPH-loaded liposome system demonstrates higher serum stability and ambient temperature stability upon storage. It exhibits increased tumor accumulation and improved animal survival in mice tumor models compared to the formulation in current clinical trials. The NCI seeks co-development partners and/or corporate licensees for the application of the technology as an anti-cancer therapeutic.

Diagnostic Assay for Determining Patient Response to Apoptosis-related Cancer Therapy

Researchers at the National Cancer Institute (NCI) developed a multiplex assay to determine the efficacy of apoptosis-related drugs targeting the Bcl2 family of proteins or aid in the selection of cancer patients likely to respond. The NCI seeks partners for co-development or licensees for commercialization of novel immunoassays for determining or predicting patient response to cancer therapy.

The Biospecimen Pre-analytical Variables (BPV) Program

The Biorepositories and Biospecimen Research Branch (BBRB) at the National Cancer Institute (NCI) has sponsored various initiatives for conducting biospecimen research. Through these initiatives, NCI seeks to advance biospecimen science and improve research reproducibility by investigating how different biospecimen collection, handling and processing procedures affect biospecimen molecular profiles. BBRB is seeking collaborators to extend these studies.

Efficient Cell-Free Production of Papillomavirus Gene Transfer Vectors

Researchers at the National Cancer Institute (NCI) developed cell free methods for efficiently producing high titer, papillomavirus virus-based gene transfer vectors. These vectors can potentially be used for vaccines and/or cancer therapeutic applications. NCI seeks licensing and/or co-development research collaborations for further development of these vectors.

New Insect Sf9-ET Cell Line for Determining Baculovirus Titers

The National Cancer Institute (NCI) seeks licensing partners for a novel modified insect cell line, Sf9-ET, that can quickly and efficiently determine baculovirus titers during the expression of recombinant proteins from a baculovirus-based protein expression system.

Methods for Producing Stem Cell-Like Memory T Cells for Use in T Cell-Based Immunotherapies

Researchers at the National Cancer Institute (NCI) seek research & co-development and/or licensees for a novel, ex vivo method by which stem cell-like memory T cells (Tscm) can be generated by stimulating naïve T cells in the presence of inhibitors of GSK-3beta, which are capable of activating the Wnt pathway. These Tscm cells, generated using GSK-3beta inhibitors, display enhanced survival and proliferation upon transfer, have multipotent capacity to generate all memory and effector T cell subsets, and show increased anti-tumor activity in a humanized mouse tumor model.

Renal Selective Unsaturated Englerin Analogues

Researchers at the National Cancer Institute (NCI) have developed a number of analogs of the natural product englerin A, an inhibitor of renal cancer cell growth. Englerin A is thought to exert its anticancer effects by activating protein kinase C (PKC) theta, and exert cytotoxic effects through activation of transient receptor potential cation (TRPC) channels. The invention englerin analogues provide promising treatment strategies for various cancers, diabetes, and HIV, and other diseases associated with the PKC theta and/or TRPC ion channel proteins. Researchers at the NCI seek licensing and/or co-development research collaborations for englerin A analogue compounds.

Targeted RNA/DNA Nanoparticles with Single Stranded RNA Toeholds

The technology is directed to the use of single-stranded RNA overhangs or toeholds of varying lengths (< 12 nucleotides) contained in nucleic acid-based nanoparticles which trigger the association of these nanoparticles and activates multiple functionalities such as gene silencing and/or cell-specific targeting. The use of RNA toeholds is superior to that of DNA toeholds in that it allows for smaller nanoparticles (fewer nucleotides for the toeholds) resulting in greater chemical stability, less immunogenic and higher yield of production. The National Cancer Institute (NCI) seeks licensing and/or co-development research collaborations for use of RNA overhangs or toeholds in nucleic acid nanoparticles.

Polymeric Delivery Platform for Therapeutics

The National Cancer Institute (NCI) seeks licensing and/or co-development research collaborations for a polymeric drug delivery platform that targets scavenger receptor A1 (SR-A1), a receptor highly expressed in macrophages, monocytes, mast cells, dendritic cells (myeloid lineages), and endothelial cells. The platform delivers various immunomodulatory therapeutic cargo including small molecule drugs, therapeutic peptides, and vaccines, to the lymphatic system and myeloid/antigen presenting cell (APC) sub-populations.

A peptide hydrogel for use in vascular anastomosis

Surgery specialists from Johns Hopkins University, in collaboration with researchers at the National Cancer Institute (NCI), developed peptide hydrogel compositions and methods to suture blood vessels during microsurgery. The hydrogels particularly benefit surgeons in whole tissue transplant procedures. The NCI seeks co-development research collaborations for further development of this technology.

Micro-Dose Calibrator for Pre-clinical Radiotracer Assays

Pre-clinical radiotracer biomedical research involves the use of compounds labeled with radioisotopes, including radio-ligand bio-distribution studies, cell binding studies, immune cell labeling techniques, and α-based therapies. Before this Micro-Dose Calibrator, measurement of pre-clinical level dosage for small animal studies was inaccurate and unreliable. This dose calibrator is a prototype ready for customer testing and scale-up. It is designed to accurately measure radioactive doses in the range of 50 nCi (1.8 kBq) to 100 µCi (3.7 MBq) with 99% precision. The NCI seeks co-development or licensing to commercialize it. Alternative uses will be considered.

Functionally-Interdependent Shape-Switching Nucleic Acid Nanoparticles

Researchers at the National Cancer Institute (NCI) have developed nucleic-acid-based nanoparticle that can be adapted for RNA interference (RNAi), molecular imaging, or a combination thereof. The invention nanoparticles can be used as therapeutics in the treatment of cancer, whichthe NCI seeks parties to license or co-develop.

Pages